Cargando…

Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients

BACKGROUND: Intrathecal immunoglobulin M (IgM) synthesis has been demonstrated in the early disease stages of multiple sclerosis (MS) as a predictor factor of a worsening disease course. Similarly, increased cerebrospinal fluid (CSF) molecules related to B-cell intrathecal activity have been associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Magliozzi, Roberta, Mazziotti, Valentina, Montibeller, Luigi, Pisani, Anna I., Marastoni, Damiano, Tamanti, Agnese, Rossi, Stefania, Crescenzo, Francesco, Calabrese, Massimiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596330/
https://www.ncbi.nlm.nih.gov/pubmed/33192314
http://dx.doi.org/10.3389/fncel.2020.569827
_version_ 1783602089490907136
author Magliozzi, Roberta
Mazziotti, Valentina
Montibeller, Luigi
Pisani, Anna I.
Marastoni, Damiano
Tamanti, Agnese
Rossi, Stefania
Crescenzo, Francesco
Calabrese, Massimiliano
author_facet Magliozzi, Roberta
Mazziotti, Valentina
Montibeller, Luigi
Pisani, Anna I.
Marastoni, Damiano
Tamanti, Agnese
Rossi, Stefania
Crescenzo, Francesco
Calabrese, Massimiliano
author_sort Magliozzi, Roberta
collection PubMed
description BACKGROUND: Intrathecal immunoglobulin M (IgM) synthesis has been demonstrated in the early disease stages of multiple sclerosis (MS) as a predictor factor of a worsening disease course. Similarly, increased cerebrospinal fluid (CSF) molecules related to B-cell intrathecal activity have been associated with a more severe MS progression. However, whether CSF levels of IgM are linked to specific inflammatory and clinical profile in MS patients at the time of diagnosis remains to be elucidated. METHODS: Using customized Bio-Plex assay, the protein levels of IgG, IgA, IgM, and of 34 other inflammatory molecules, related to B-cell, T-cell, and monocyte/macrophage activity, were analyzed in the CSF of 103 newly diagnosed relapsing–remitting MS patients and 36 patients with other neurological disorders. CSF IgM levels were also correlated with clinical and neuroradiological measures [advanced 3-T magnetic resonance imaging (MRI) parameters], at diagnosis and after 2 years of follow-up. RESULTS: A 45.6% increase in CSF IgM levels was found in MS patients compared to controls (p = 0.013). CSF IgM levels correlated with higher CSF levels of CXCL13 (p = 0.039), CCL21 (p = 0.023), interleukin 10 (IL-10) (p = 0.025), IL-12p70 (p = 0.020), CX3CL1 (p = 0.036), and CHI3L1 (p = 0.048) and were associated with earlier age of patients at diagnosis (p = 0.008), white matter lesion (WML) number (p = 0.039) and disease activity (p = 0.033) after 2 years of follow-up. CONCLUSION: IgMs are the immunoglobulins mostly expressed in the CSF of naive MS patients compared to other neurological conditions at the time of diagnosis. The association between increased CSF IgM levels and molecules related to both B-cell immunity (IL-10) and recruitment (CXCL13 and CCL21) and to macrophage/microglia activity (IL-12p70, CX3CL1, and CHI3L1) suggests possible correlation between humoral and innate intrathecal immunity in early disease stage. Furthermore, the association of IgM levels with WMLs and MS clinical and MRI activity after 2 years supports the idea of key role of IgM in the disease course.
format Online
Article
Text
id pubmed-7596330
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75963302020-11-13 Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients Magliozzi, Roberta Mazziotti, Valentina Montibeller, Luigi Pisani, Anna I. Marastoni, Damiano Tamanti, Agnese Rossi, Stefania Crescenzo, Francesco Calabrese, Massimiliano Front Cell Neurosci Neuroscience BACKGROUND: Intrathecal immunoglobulin M (IgM) synthesis has been demonstrated in the early disease stages of multiple sclerosis (MS) as a predictor factor of a worsening disease course. Similarly, increased cerebrospinal fluid (CSF) molecules related to B-cell intrathecal activity have been associated with a more severe MS progression. However, whether CSF levels of IgM are linked to specific inflammatory and clinical profile in MS patients at the time of diagnosis remains to be elucidated. METHODS: Using customized Bio-Plex assay, the protein levels of IgG, IgA, IgM, and of 34 other inflammatory molecules, related to B-cell, T-cell, and monocyte/macrophage activity, were analyzed in the CSF of 103 newly diagnosed relapsing–remitting MS patients and 36 patients with other neurological disorders. CSF IgM levels were also correlated with clinical and neuroradiological measures [advanced 3-T magnetic resonance imaging (MRI) parameters], at diagnosis and after 2 years of follow-up. RESULTS: A 45.6% increase in CSF IgM levels was found in MS patients compared to controls (p = 0.013). CSF IgM levels correlated with higher CSF levels of CXCL13 (p = 0.039), CCL21 (p = 0.023), interleukin 10 (IL-10) (p = 0.025), IL-12p70 (p = 0.020), CX3CL1 (p = 0.036), and CHI3L1 (p = 0.048) and were associated with earlier age of patients at diagnosis (p = 0.008), white matter lesion (WML) number (p = 0.039) and disease activity (p = 0.033) after 2 years of follow-up. CONCLUSION: IgMs are the immunoglobulins mostly expressed in the CSF of naive MS patients compared to other neurological conditions at the time of diagnosis. The association between increased CSF IgM levels and molecules related to both B-cell immunity (IL-10) and recruitment (CXCL13 and CCL21) and to macrophage/microglia activity (IL-12p70, CX3CL1, and CHI3L1) suggests possible correlation between humoral and innate intrathecal immunity in early disease stage. Furthermore, the association of IgM levels with WMLs and MS clinical and MRI activity after 2 years supports the idea of key role of IgM in the disease course. Frontiers Media S.A. 2020-10-16 /pmc/articles/PMC7596330/ /pubmed/33192314 http://dx.doi.org/10.3389/fncel.2020.569827 Text en Copyright © 2020 Magliozzi, Mazziotti, Montibeller, Pisani, Marastoni, Tamanti, Rossi, Crescenzo and Calabrese. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Magliozzi, Roberta
Mazziotti, Valentina
Montibeller, Luigi
Pisani, Anna I.
Marastoni, Damiano
Tamanti, Agnese
Rossi, Stefania
Crescenzo, Francesco
Calabrese, Massimiliano
Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients
title Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients
title_full Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients
title_fullStr Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients
title_full_unstemmed Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients
title_short Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients
title_sort cerebrospinal fluid igm levels in association with inflammatory pathways in multiple sclerosis patients
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596330/
https://www.ncbi.nlm.nih.gov/pubmed/33192314
http://dx.doi.org/10.3389/fncel.2020.569827
work_keys_str_mv AT magliozziroberta cerebrospinalfluidigmlevelsinassociationwithinflammatorypathwaysinmultiplesclerosispatients
AT mazziottivalentina cerebrospinalfluidigmlevelsinassociationwithinflammatorypathwaysinmultiplesclerosispatients
AT montibellerluigi cerebrospinalfluidigmlevelsinassociationwithinflammatorypathwaysinmultiplesclerosispatients
AT pisaniannai cerebrospinalfluidigmlevelsinassociationwithinflammatorypathwaysinmultiplesclerosispatients
AT marastonidamiano cerebrospinalfluidigmlevelsinassociationwithinflammatorypathwaysinmultiplesclerosispatients
AT tamantiagnese cerebrospinalfluidigmlevelsinassociationwithinflammatorypathwaysinmultiplesclerosispatients
AT rossistefania cerebrospinalfluidigmlevelsinassociationwithinflammatorypathwaysinmultiplesclerosispatients
AT crescenzofrancesco cerebrospinalfluidigmlevelsinassociationwithinflammatorypathwaysinmultiplesclerosispatients
AT calabresemassimiliano cerebrospinalfluidigmlevelsinassociationwithinflammatorypathwaysinmultiplesclerosispatients